Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (DERMIS-OLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04286607
Recruitment Status : Enrolling by invitation
First Posted : February 27, 2020
Last Update Posted : April 30, 2020
Sponsor:
Information provided by (Responsible Party):
Arcutis Biotherapeutics, Inc.

Brief Summary:
This study will assess the safety and efficacy of ARQ-151 cream applied once a day for 24 weeks by subjects with chronic plaque psoriasis

Condition or disease Intervention/treatment Phase
Chronic Plaque Psoriasis Drug: Topical roflumilast Phase 3

Detailed Description:
This is an open-label study in which ARQ-151 cream is applied once daily x 24 weeks to subjects with psoriasis

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis Who Have Completed Preceding Studies ARQ-151-301 or ARQ-151-302
Actual Study Start Date : February 12, 2020
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Roflumilast

Arm Intervention/treatment
Experimental: ARQ-151 Cream 0.3% Drug: Topical roflumilast
Active treatment
Other Name: ARQ-151 Cream 0.3%




Primary Outcome Measures :
  1. Occurrence of treatment emergent AEs (TEAEs) [ Time Frame: 24 weeks ]
    The occurrence of TEAEs and the occurrence of (Serious Adverse Events) SAEs


Secondary Outcome Measures :
  1. Achievement of an Investigator Global Assessment (IGA) of 'clear' or 'almost clear' over time. [ Time Frame: 24 weeks ]
  2. In subjects who achieve a 'clear' IGA time to re-starting investigational product (duration of response). [ Time Frame: 24 weeks ]
  3. Achievement of a 50% reduction in (Psoriasis Area Severity Index) PASI over time [ Time Frame: 24 weeks ]
  4. Achievement of a 75% reduction in PASI over time [ Time Frame: 24 weeks ]
  5. Achievement of a 90% reduction in PASI over time [ Time Frame: 24 weeks ]
  6. Achievement of a 100% reduction in PASI over time [ Time Frame: 24 weeks ]
  7. Change in Worst Itch Numeric Rating Scale) WI-NRS score over time [ Time Frame: 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants legally competent to sign and give informed consent
  • Males and females ages 12 years and older (inclusive)
  • Subjects with chronic plaque psoriasis who met eligibility criteria for and successfully completed either study ARQ-151-301 or ARQ-151-302 through Week 8, and are able to enroll into this long-term safety study on the Week 8 visit of the previous study.
  • Females of childbearing potential (FOCBP) must have a negative pregnancy test at all study visits. In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.

Exclusion Criteria:

  • Subjects who experienced an ARQ-151 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-151 cream in Studies ARQ-151-301 or ARQ-151-302.
  • Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
  • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  • Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of investigational product.
  • Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04286607


Locations
Show Show 79 study locations
Sponsors and Collaborators
Arcutis Biotherapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: David Berk, MD Arcutis Biotherapeutics, Inc.
Layout table for additonal information
Responsible Party: Arcutis Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04286607    
Other Study ID Numbers: ARQ-151-306
First Posted: February 27, 2020    Key Record Dates
Last Update Posted: April 30, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases